Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study
| Autor: | Daniel B. Shin, Joel M. Gelfand, Alexis Ogdie, Kashif Jafri, Christie M. Bartels |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
030203 arthritis & rheumatology
medicine.medical_specialty education.field_of_study Cross-sectional study Proportional hazards model business.industry Incidence (epidemiology) Population Arthritis medicine.disease 03 medical and health sciences Psoriatic arthritis 0302 clinical medicine Rheumatology Rheumatoid arthritis Internal medicine medicine Physical therapy 030212 general & internal medicine education business Cohort study |
| Zdroj: | Arthritis Care & Research. 69:51-57 |
| ISSN: | 2151-464X |
| DOI: | 10.1002/acr.23094 |
| Popis: | Objectives: To examine the prevalence and incidence of cardiovascular risk factors (CVRFs) including hypertension (HTN), hyperlipidemia (HL), diabetes mellitus (DM), and obesity among patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA) compared to the general population, and to examine the treatment of incident CVRFs in PsA and RA compared to controls. Methods: A cohort study was conducted within The Health Improvement Network, a medical record database in the United Kingdom, using data from 1994 to 2014. Patients age 18-89 with PsA or RA were matched to controls on practice and start date. The prevalence and incidence of CVRFs identified by diagnostic codes were calculated. Cox proportional hazards models were used to examine the relative incidence of these cardiovascular risk factors. Finally, pharmacologic therapies for incident CVRFs were examined. Results: Study subjects included patients with PsA (N=12,548), RA (N=53,215), and controls (N=389,269). The prevalence of all CVRFs was significantly elevated in PsA. Only the prevalence of DM and obesity was increased in RA. Incidence of HTN, HL, and DM was elevated in PsA and RA. Receipt of therapy within one year following incident diagnosis of CVRFs was not substantially different between the groups; approximately 85%, 65%, and 45% of patients received prescriptions for HTN, HL, and DM, respectively. Conclusion: Patients with PsA have an increased prevalence of CVRFs, and both patients with PsA and RA have increased incidence of new diagnosis of CVRFs. Pharmacologic treatment of CVRFs in patients with PsA and RA was similar to controls in the UK. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text